TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8497679

Group type: EXPERIMENTAL
Intervention: Terbutaline (500 micrograms)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Terbutaline plus ipratropium bromide (20 micrograms)
Number of subjects: 21
Study: 3545941

Group type: EXPERIMENTAL
Intervention: Bacampicillin 400 mg twice daily
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg twice daily
Number of subjects: 953

Group type: COMPARATOR
Intervention: Three times daily dosages of bacampicillin, ampicillin, amoxycillin
Number of subjects: 953

Group type: COMPARATOR
Intervention: Co-trimoxazole twice daily
Number of subjects: 953
Study: 31821154

Group type: EXPERIMENTAL
Intervention: Digital self-monitoring intervention (EMPOWER) using a mobile app for early warning signs monitoring.
Number of subjects: 0
Study: 29475554

Group type: EXPERIMENTAL
Intervention: DIAGNOdent (KaVo)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Spectra (Air Techniques)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No device
Number of subjects: 1500
Study: 27829457

Group type: EXPERIMENTAL
Intervention: Dietary intervention group receiving dietary advice
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group receiving only advice on the care and maintenance of dentures
Number of subjects: 70
Study: 24704505

Group type: EXPERIMENTAL
Intervention: Live attenuated tetravalent bovine-human reassortant rotavirus vaccine (BRV-TV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22411179

Group type: EXPERIMENTAL
Intervention: Standard part-list cueing condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gradual part-list cueing condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-cueing condition
Number of subjects: 0
Study: 19281324

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) group received a 12-week lifestyle intervention
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Minimum Intervention (MI) group
Number of subjects: 1021
Study: 17188743

Group type: EXPERIMENTAL
Intervention: Substance use immediately preceding mania
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Substance use preceding mania
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Substance use following mania
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Indeterminable substance use
Number of subjects: 170
Study: 15820074

Group type: EXPERIMENTAL
Intervention: Combined therapy (intraoperative hypotonic peritoneal chemo-hyperthermia and early postoperative intraperitoneal chemotherapy)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Treatment groups 1 and 2 (combined therapy and intraoperative chemotherapy)
Number of subjects: 156
Study: 12549803

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg/dose for three doses given at 24 hourly intervals)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Indomethacin (0.2 mg/kg/dose for three doses given at 12 hourly intervals)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen and Indomethacin
Number of subjects: 18
Study: 9798586

Group type: EXPERIMENTAL
Intervention: Albendazole 1200 mg
Number of subjects: 622

Group type: COMPARATOR
Intervention: Pyrantel
Number of subjects: 622
Study: 7858933

Group type: COMPARATOR
Intervention: MTC 20 mg i.v. at time zero, MTC 20 mg i.m. after 4 h and 8 h (parenteral injections)
Number of subjects: 12

Group type: COMPARATOR
Intervention: MTC 40 mg by nasal spray 2 h before chemotherapy, followed by the same dose at 4 h and 8 h (nasal spray)
Number of subjects: 12
Study: 2488281

Group type: COMPARATOR
Intervention: Zidovudine (AZT); specific dosage and duration not mentioned
Number of subjects: 0
Study: 31073189

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) elements
Number of subjects: 176
Study: 28552257

Group type: EXPERIMENTAL
Intervention: Nebulized liposomal amphotericin B (LAmB) maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional strategy without antifungal maintenance therapy
Number of subjects: 0
Study: 25918337

Group type: EXPERIMENTAL
Intervention: Patient safety culture questionnaire
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient safety culture questionnaire + practice-based workshop
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 30
Study: 23691884

Group type: EXPERIMENTAL
Intervention: Resistive heating (RH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Convective warming (CW)
Number of subjects: 70
Study: 21348793

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day) for 8 weeks
Number of subjects: 104
Study: 19731700

Group type: EXPERIMENTAL
Intervention: Lifestraw Personal water treatment device
Number of subjects: 313

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 313
Study: 17210398

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Four-layer bandages
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Knitted viscose dressings
Number of subjects: 245
Study: 15542181

Group type: EXPERIMENTAL
Intervention: CpG 7909
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alum-adsorbed HBsAg
Number of subjects: 0
Study: 15019322

Group type: EXPERIMENTAL
Intervention: Topical 0.05% cyclosporin A eyedrops
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 22
Study: 11262208

Group type: EXPERIMENTAL
Intervention: pyrimethamine‐sulfadoxine and 3 doses of artesunate
Number of subjects: 0

Group type: COMPARATOR
Intervention: pyrimethamine‐sulfadoxine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: artesunate (1 or 3 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: pyrimethamine‐sulfadoxine
Number of subjects: 0
Study: 9272590

Group type: EXPERIMENTAL
Intervention: Hypoglycaemia (at around 3 mmol l(‐1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Euglycaemia
Number of subjects: 15
Study: 8327279

Group type: EXPERIMENTAL
Intervention: Bovine surfactant treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no surfactant treatment)
Number of subjects: 47
Study: 3563430

Group type: EXPERIMENTAL
Intervention: Sulfadiazine-trimethoprim combination (500 mg + 150 mg) b.i.d. for 3 days
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sulfadiazine-trimethoprim combination (500 mg + 150 mg) b.i.d. for 10 days
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pivmecillinam (500 mg) t.i.d. for 3 days
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pivmecillinam (500 mg) t.i.d. for 10 days
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sulfadiazine-trimethoprim combination (10-day regimen)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Sulfadiazine-trimethoprim (3-day regimen)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sulfadiazine-trimethoprim (3-day regimen) and Pivmecillinam (3-day regimen)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sulfadiazine-trimethoprim (10-day regimen) and Pivmecillinam (10-day regimen)
Number of subjects: 132
Study: 28967984

Group type: EXPERIMENTAL
Intervention: SYM‐1219 2 g
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: SYM‐1219 6 g
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 52
Study: 27440710

Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg intravenously once per year)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Alendronate (70 mg orally once per week)
Number of subjects: 105
Study: 24458543

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Insomnia (CBT-I)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 113
Study: 23990917

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 564

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Wnt‐5a expression
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Wnt‐5a expression in Luminal A tumors
Number of subjects: 564
Study: 20524443

Group type: EXPERIMENTAL
Intervention: Nicomild‐2 Sugar Free Gum (2 mg pieces, 6.74%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nicorette Sugar Free (2 mg pieces)
Number of subjects: 24
Study: 18514508

Group type: EXPERIMENTAL
Intervention: Exemestane 25mg daily and celecoxib 400mg twice daily (group A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Exemestane 25mg daily (group B)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Letrozole 2.5mg daily (group C)
Number of subjects: 82
Study: 16616168

Group type: EXPERIMENTAL
Intervention: Audio Computer‐Assisted Self‐Interview (ACASI)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Interviewer‐Administered Questionnaire (IAQ)
Number of subjects: 735
Study: 12631367

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1513
Study: 10388245

Group type: EXPERIMENTAL
Intervention: Patients with unmet needs
Number of subjects: 94
Study: 8891805

Group type: EXPERIMENTAL
Intervention: Magnesium infusion
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study: 1495197

Group type: EXPERIMENTAL
Intervention: Cefdinir 3 mg/kg administered 1 hour before meal (fasting state)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefdinir 3 mg/kg administered 30 minutes after meal
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cefdinir mean dose of 4.8 mg/kg t.i.d. for 8 days
Number of subjects: 17
Study: 6488805

Group type: EXPERIMENTAL
Intervention: Not applicable (no specific intervention mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (no specific control mentioned)
Number of subjects: 0
Study: 31917467

Group type: EXPERIMENTAL
Intervention: Continuous event recording (R-test 4; Novacor)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Intermittent ECG (Zenicor II)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Continuous event recording
Number of subjects: 269

Group type: COMPARATOR
Intervention: Intermittent ECG
Number of subjects: 269
Study: 30660059

Group type: EXPERIMENTAL
Intervention: Yoga intervention (4 sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 44
Study: 28045051

Group type: EXPERIMENTAL
Intervention: Combined physical-cognitive training for 7 months
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual life (control group)
Number of subjects: 113
Study: 26003882

Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway (SLMA)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Face Mask
Number of subjects: 142
Study: 23588865

Group type: EXPERIMENTAL
Intervention: 5 mg/ml (total 2 ml) esmolol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2 ml saline
Number of subjects: 90
Study: 21271613

Group type: EXPERIMENTAL
Intervention: Zibotentan 15 mg plus docetaxel 75 mg/m²
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo plus docetaxel 75 mg/m²
Number of subjects: 26
Study: 19558010

Group type: EXPERIMENTAL
Intervention: Albuterol use
Number of subjects: 114

Group type: COMPARATOR
Intervention: Caregiver report of having an asthma action plan (AAP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Recent primary care physician visit
Number of subjects: 114
Study: 17765472

Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum/plasma biomarkers
Number of subjects: 0
Study: 15166570

Group type: EXPERIMENTAL
Intervention: Sufentanil 10 microg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sufentanil 30 microg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Morphine 0.3 mg
Number of subjects: 2
Study: 12002497

Group type: EXPERIMENTAL
Intervention: Intravenous regional blockade (IVRB) with 15 mg of guanethidine in 30 ml of 0.5% prilocaine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Serial IVRB with 30 ml of normal saline (control)
Number of subjects: 57
Study: 9861128

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 35
Study: 7881929

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Surgery without delay
Number of subjects: 52
Study: 1965420

Group type: EXPERIMENTAL
Intervention: 200 mg of itraconazole given in one single day
Number of subjects: 552

Group type: COMPARATOR
Intervention: 200 mg twice daily for one day
Number of subjects: 552

Group type: COMPARATOR
Intervention: 200 mg once daily for two days
Number of subjects: 552

Group type: COMPARATOR
Intervention: 200 mg once daily for three days
Number of subjects: 552
Study: 354304

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Number of subjects: 0
Study: 6802327

Group type: EXPERIMENTAL
Intervention: Slow-release aminophylline (14 mg/kg twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 30947585

Group type: EXPERIMENTAL
Intervention: Blinatumomab by continuous infusion for 4 weeks in 6‐week cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard salvage chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blinatumomab as later salvage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blinatumomab and chemotherapy
Number of subjects: 0
Study: 28985278

Group type: EXPERIMENTAL
Intervention: WATER (aquatic exercise)
Number of subjects: 24
Study: 27474376

Group type: EXPERIMENTAL
Intervention: 6-year nurse-led, multidomain cardiovascular intervention
Number of subjects: 3526

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3526
Study: 24861441

Group type: EXPERIMENTAL
Intervention: Low luminance intermittent photic stimulation (IPS) in JME patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Low luminance intermittent photic stimulation (IPS) in healthy controls
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dynamic evaluation of BOLD signal changes related to photoparoxysmal response (PPR) in JME patients
Number of subjects: 13
Study: 22810591

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus an induction regimen of antiangiogenesis and antitumor immunity (G2); induction regimen included low dose metronomic cyclophosphamide, high dose Cox‐2 inhibitor, granulocyte colony‐stimulating factor, a sulfhydryl donor, and a hemoderivative with autologous tumor antigens.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard chemotherapy (G1); used as control group.
Number of subjects: 60
Study: 20213592

Group type: EXPERIMENTAL
Intervention: 1 fps frame rate
Number of subjects: 107

Group type: COMPARATOR
Intervention: 2 fps frame rate (control)
Number of subjects: 107
Study: 17272293

Group type: EXPERIMENTAL
Intervention: Supervised group exercise led by an expert instructor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Talk-based support group
Number of subjects: 0
Study: 14993132

Group type: EXPERIMENTAL
Intervention: Class III CHF
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Combination of LVEF <0.20 and class III symptoms
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Overall ICD discharges
Number of subjects: 1140
Study: 11770315

Group type: EXPERIMENTAL
Intervention: Combination therapy (INF + Ribavirin) for 6 months
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Monotherapy (INF) for 18 months
Number of subjects: 445

Group type: COMPARATOR
Intervention: Interferon alone for 6 months
Number of subjects: 445
Study: 9293649

Group type: EXPERIMENTAL
Intervention: Epidural butorphanol 0.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural butorphanol 0.5 mg plus clonidine 75 micrograms
Number of subjects: 60
Study: 7905413

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2825502

Group type: EXPERIMENTAL
Intervention: Fiber supplements (three different types)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-fiber control
Number of subjects: 12
Study: 27288054

Group type: EXPERIMENTAL
Intervention: Highly personalised, interactive, one-on-one feedback intervention for CAUTI diagnosis; details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based, report-style feedback intervention for hypertension care; details on dosage and duration not specified.
Number of subjects: 0
Study: 25653199

Group type: EXPERIMENTAL
Intervention: Drinktest plus prototype alteration
Number of subjects: 2634

Group type: EXPERIMENTAL
Intervention: Drinktest plus cue reminder
Number of subjects: 2634

Group type: EXPERIMENTAL
Intervention: Drinktest plus prototype alteration and cue reminder
Number of subjects: 2634

Group type: COMPARATOR
Intervention: Original Drinktest
Number of subjects: 2634
Study: 24621255

Group type: EXPERIMENTAL
Intervention: Exenatide BID (5 µg for 4 weeks, then 10 µg ongoing)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 22348698

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD) + Coronally Advanced Flap (CAF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Subepithelial Connective Tissue Graft (CTG) + Coronally Advanced Flap (CAF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Comparison between EMD + CAF and CTG + CAF
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (EMD)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Subepithelial Connective Tissue Graft (CTG)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Patient Satisfaction
Number of subjects: 9
Study: 19430303

Group type: EXPERIMENTAL
Intervention: AIDS-defining events (ADEs)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Non-AIDS serious adverse events (SAEs)
Number of subjects: 368
Study: 17761059

Group type: EXPERIMENTAL
Intervention: Telephone-option for asthma reviews
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Face-to-face-only reviews
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 1809
Study: 16398429

Group type: EXPERIMENTAL
Intervention: Shengmai injection (SI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 64
Study: 11181656

Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide 400 mg/m(2) IV, epirubicin 50 mg/m(2) IV, and fluorouracil 500 mg/m(2) IV on days 1 and 8)
Number of subjects: 460

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 500 mg/m(2) IV, methotrexate 40 mg/m(2) IV, and fluorouracil 600 mg/m(2) IV on days 1 and 8)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: CEF
Number of subjects: 460

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 460
Study: 9710013

Group type: EXPERIMENTAL
Intervention: Echoplanar magnetic resonance perfusion imaging (PI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pattern of PI lesion larger than DWI lesion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pattern of DWI lesion but no PI lesion
Number of subjects: 18
Study: 7846930

Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacing
Number of subjects: 30
Study: 3059899

Group type: EXPERIMENTAL
Intervention: Theophylline at mean concentrations of 5.13, 12.07, and 18.6 micrograms/ml
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30717227

Group type: EXPERIMENTAL
Intervention: Counselling based on motivational interviewing (MI) on healthy eating and physical activity
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Healthy eating alone
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Physical activity alone
Number of subjects: 436

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 436
Study: 28743315

Group type: EXPERIMENTAL
Intervention: Tight blood pressure control
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 75
Study: 26188198

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no posterior pericardiotomy)
Number of subjects: 200
Study: 23388508

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FC)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate followed by allogeneic blood products (FC+FFP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (FFP)
Number of subjects: 61
Study: 22093569

Group type: EXPERIMENTAL
Intervention: CarFit intervention
Number of subjects: 195

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 195
Study: 19604642

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (22.2±2.0 mg/h/70 kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17341752

Group type: EXPERIMENTAL
Intervention: Parental reporting of AOM episodes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Parental interview method
Number of subjects: 120
Study: 15456342

Group type: EXPERIMENTAL
Intervention: Intravenous anidulafungin 50 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral fluconazole 100 mg/day
Number of subjects: 0
Study: 11552994

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin and low molecular weight heparin (dalteparin) during heparin prophylaxis at 30 weeks of gestation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis (regardless of type)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-heparin prophylaxis (4 months after delivery)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 pregnant women with no history of thromboembolism)
Number of subjects: 20
Study: 9522143

Group type: EXPERIMENTAL
Intervention: Prilocaine 2% (6 mL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (3 mL)
Number of subjects: 44